Highlights REGENXBIO Inc.

Equities

RGNX

US75901B1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
16.67 ^USD	-1.71%		+2.90%	-7.13%

May. 08	Earnings Flash (RGNX) REGENXBIO Posts Q1 Revenue $15.6M	MT
May. 08	REGENXBIO Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (RGNX) REGENXBIO Posts Q1 Revenue $15.6M	May. 08	MT
REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD	Mar. 28	CI
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
REGENXBIO Inc. Announces New Interim Safety and Efficacy Data from Duchenne Trial	Mar. 05	CI
Earnings Flash (RGNX) REGENXBIO Posts Q4 Revenue $22.2M	Feb. 27	MT
REGENXBIO Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
REGENXBIO Inc. Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint	Feb. 07	CI
REGENXBIO Inc Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in Duchenne Trial	Feb. 07	CI
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	Feb. 05	RE
REGENXBIO Inc. Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery	Jan. 16	CI
Health Care Up as Merger Wave Continues -- Health Care Roundup	Jan. 08	DJ
REGENXBIO Inc. Announces Dose Escalation in AFFINITY Duchenne®? Trial	Nov. 29	CI
Earnings Flash (RGNX) REGENXBIO Reports Q3 Revenue $28.9M	Nov. 08	MT
REGENXBIO Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
REGENXBIO Inc. Presents Positive One Year Data from Phase II ALTUDE®? Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery	Nov. 03	CI
Vitreous Retina Macula Consultants of New York Announces Participation in Wet AMD Study in Collaboration with Regenxbio	23-10-17	CI
REGENXBIO Inc. Announces Additional Interim Safety Data and Initial Efficacy Data from the Phase I/II AFFINITY Duchenne Trial of RGX-202	23-10-03	CI
REGENXBIO Inc. Announces Initial Clinical Data from First Pediatric CLN2 Patient Dosed with RGX-181	23-08-30	CI
Earnings Flash (RGNX) REGENXBIO Posts Q2 Revenue $20M	23-08-02	MT
REGENXBIO Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights REGENXBIO Inc.

Equities

RGNX

US75901B1070

Highlights

Filters